NY-UNIFRAX
9.9.2021 13:02:10 CEST | Business Wire | Press release
Unifrax , a leading manufacturer of high-performance specialty materials will feature their latest innovation, SiFAB™ Silicon Fiber Anode Battery Technology , at next week’s Battery Show in Novi, Michigan. Unifrax launched SiFAB earlier this year, and will feature the new silicon fiber technology during a technical presentation and exhibit during this year’s The Battery Show and Electric & Hybrid Vehicle Technology Expo at Suburban Collection Showplace, September 14-16.
Bruce Zoitos, senior scientist and manager, materials research, Unifrax, will present data obtained following advanced testing of SiFAB, which has demonstrated promising performance in multiple battery systems. SiFAB, uniquely structured for high-capacity performance, enables significantly higher energy density in lithium-ion battery systems and has successfully been tested with incremental Si loadings of greater than 40 percent. Zoitos will present these findings during a technical session on Wednesday, September 15 at 2:30 p.m. in the Crystal Room.
“Lithium-ion batteries are playing a pivotal role in our everyday life,” said Zoitos. "Along with greater energy density, SiFAB will provide faster charges and longer battery life for applications including electric vehicles, portable electronics, power tools, energy grid storage, and aerospace. With SiFAB, our recent testing shows our technology can provide a drop-in solution that can be incorporated as early as 2022, enabling better and longer-performing applications.”
The data, collected in part by Wildcat Discovery Technologies, and the Battery Innovation Center, support SiFAB’s promising performance with significantly higher capacity and fast charging capability in various electrode formulations.
According to advanced testing performed in 2021, SiFAB has demonstrated:
- Reversible capacity greater than 1,000 mAh/g enabling gravimetric energy density improvement over graphite up to 20 percent
- Robust performance in various electrode formulations which allows design flexibility to cell makers and OEMs
- Proven high-rate charge and discharge performance up to 4C
- Proven high temperature performance at 45°C
- Stable cycling with high Si loadings and minimal volume expansion. Cycling of these batteries is ongoing
- SiFAB drops into existing manufacturing process; SiFAB has been successfully applied in roll-to-roll processes in standard manufacturing scenarios
“After working with reputable battery labs and partners to test SiFAB, we’re excited to share SiFAB testing results at The Battery Show next week,” said Chad Cannan, senior vice president of research and development, Unifrax. “Our data shows SiFAB delivers strong performance in realistic cell conditions and real-world applications. With SiFAB’s promising performance, and Unifrax’s ability to scale up manufacturing with our first SiFAB manufacturing line being built at our Indiana manufacturing site now, our plan is on track for producing tens of metric tons in early 2022 with hundreds of metric tons capacity planned for 2023, making SiFAB a reality for customers,” said Cannan.
In addition to the SiFAB technical session with Bruce Zoitos, Unifrax will be available at booth #1431 during the 2021 Battery Show September 14-16, to discuss SiFAB technology with interested attendees.
To learn more about SiFAB, and to request a sample, visit www.sifab.com .
About Unifrax
Unifrax develops and manufactures high-performance specialty materials used in advanced applications, including high-temperature industrial insulation, electric vehicles, energy storage, filtration and fire protection, among many others. Unifrax products are designed with the ultimate goal of saving energy, reducing pollution and improving safety for people, buildings and equipment by delivering on our commitment to our customers of greener, cleaner, safer solutions for their application challenges. Unifrax has 37 manufacturing facilities operating in 12 countries and employs 2,700+ employees globally. More information is available at www.unifrax.com . For updates, follow us on Twitter , LinkedIn and Facebook .
About Clearlake
Clearlake Capital Group, L.P. is a leading investment firm founded in 2006 operating integrated businesses across private equity, credit and other related strategies. With a sector-focused approach, the firm seeks to partner with experienced management teams by providing patient, long-term capital to dynamic businesses that can benefit from Clearlake’s operational improvement approach, O.P.S. ® The firm’s core target sectors are industrials, technology and consumer. Clearlake currently has approximately $39 billion of assets under management, and its senior investment principals have led or co-led over 300 investments. The firm has offices in Santa Monica and Dallas. More information is available at www.clearlake.com and on Twitter @ClearlakeCap .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210909005324/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 07:00:00 CEST | Press release
Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback Regulatory filings in other territories are ongoing and remain on track Ad hoc announcement pursuant to Art. 53 LR Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufa
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 03:45:00 CEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
